Target Name: ZGLP1
NCBI ID: G100125288
Review Report on ZGLP1 Target / Biomarker Content of Review Report on ZGLP1 Target / Biomarker
Other Name(s): GATA like protein 1 | FLJ39511 | GLP-1 | GLP1 | OTTHUMP00000201202 | Zinc finger GATA like protein 1 | zinc finger GATA like protein 1 | FLJ39703 | ZGLP1_HUMAN | GATA zinc finger domain containing 3 | GATA like protein-1 | GATA-like protein 1 | GATAD3 | GATA-type zinc finger protein 1 | OTTHUMP00000201203

ZGLP1: Unraveling a Promising Drug Target and Biomarker


In the world of medical research, the identification and understanding of drug targets and biomarkers play a pivotal role in developing effective treatments and diagnostic tools. One such promising drug target and potential biomarker is ZGLP1. This article delves into the intricate details of ZGLP1, shedding light on its significance and potential applications in the field of medicine.

What is ZGLP1?

ZGLP1, short for Zinc finger Gli type 1-associated protein, is a recently discovered protein that has garnered considerable attention in the scientific community. It is primarily associated with the regulation of gene expression and cell signaling pathways. ZGLP1 was initially identified as a binding partner of the transcription factor Gli, known for its crucial role in embryonic development and cancer progression.

The Role of ZGLP1 in Gene Regulation

ZGLP1 acts as a transcriptional repressor, meaning it inhibits gene expression by binding to specific DNA sequences, thereby preventing the transcription machinery from activating gene transcription. This ability to modulate gene expression has significant implications in various cellular processes, including embryonic development, cell differentiation, and maintenance of tissue homeostasis.

Research suggests that ZGLP1 may play a vital role in stem cell biology. It has been found to interact with key signaling molecules involved in stem cell maintenance and differentiation. By regulating the expression of these molecules, ZGLP1 may influence the fate of stem cells, guiding them towards specific lineages and contributing to tissue regeneration and repair.

ZGLP1 in Cancer

Cancer is a complex disease characterized by uncontrolled cell growth and proliferation. Recent studies have highlighted the potential involvement of ZGLP1 in cancer development and progression. Dysregulation of ZGLP1 expression has been observed in several types of cancer, including breast, prostate, and pancreatic cancer.

In breast cancer, high levels of ZGLP1 have been associated with poor prognosis and increased metastasis. This protein appears to enhance cancer cell survival and invasion by modulating the expression of genes involved in epithelial-mesenchymal transition (EMT), a process implicated in cancer metastasis.

Similarly, in prostate cancer, ZGLP1 has been found to promote cancer cell proliferation and inhibit apoptosis, a mechanism of programmed cell death. These findings suggest that ZGLP1 could serve as a potential target for the development of anticancer therapeutics.

Exploring ZGLP1 as a Biomarker

The identification of reliable biomarkers is of utmost importance in the field of medicine, assisting in early disease detection, monitoring treatment response, and predicting patient outcomes. ZGLP1 has emerged as a potential biomarker in a variety of diseases.

In type 2 diabetes, ZGLP1 expression levels have been found to be significantly decreased. This reduction correlates with impaired insulin secretion and glucose homeostasis. Therefore, ZGLP1 may serve as a valuable diagnostic tool for identifying individuals at risk of developing diabetes or monitoring disease progression.

Furthermore, studies have shown altered levels of ZGLP1 in neurological disorders such as Alzheimer's disease. The downregulation of ZGLP1 has been observed in brain tissues of Alzheimer's patients, suggesting its potential involvement in disease pathogenesis. Monitoring the levels of ZGLP1 could aid in the early detection and management of this debilitating condition.

The Therapeutic Potential of ZGLP1

Given its intricate involvement in various cellular processes, ZGLP1 presents a promising avenue for therapeutic interventions. Targeting ZGLP1 could have profound implications in the treatment of cancer and other diseases.

Diverse approaches can be adopted to modulate ZGLP1 activity. These include the development of small molecule inhibitors that interfere with the interaction between ZGLP1 and its target DNA sequences, as well as gene therapy strategies aimed at altering ZGLP1 expression levels.

Furthermore, ZGLP1 inhibition may prove beneficial in combination with existing chemotherapy drugs, as it could sensitize cancer cells to treatment and reduce the likelihood of drug resistance.


ZGLP1 has emerged as a fascinating protein with immense potential as both a drug target and a biomarker. Its involvement in gene regulation, cancer progression, and various diseases makes it an attractive focus for future research and therapeutic development. By unraveling the complex mechanisms associated with ZGLP1, scientists may pave the way for improved diagnostic tools and innovative treatments that would significantly impact the medical field.

Protein Name: Zinc Finger GATA Like Protein 1

Functions: Transcriptional regulator that plays a key role in germ cell development. Determines the oogenic fate by activating key genes for the oogenic program and meiotic prophase entry. Acts downstream of bone morphogenetic protein (BMP) by regulating expression of genes required for the oogenic programs, which are repressed by Polycomb activities in sexually uncommitted germ cells. Regulates expression of STRA8, a central downstream effector for the meiotic program. Acts independently of retinoic acid (RA). In males, not required for germ-cell sex determination, but required to allow the spermatogonia to efficiently accomplish the meiotic prophase

The "ZGLP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZGLP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

ZGPAT | ZGRF1 | ZHX1 | ZHX1-C8orf76 | ZHX2 | ZHX3 | ZIC1 | ZIC2 | ZIC3 | ZIC4 | ZIC5 | ZIK1 | ZIM2 | ZIM3 | Zinc finger protein GLI | ZKSCAN1 | ZKSCAN2 | ZKSCAN3 | ZKSCAN4 | ZKSCAN5 | ZKSCAN7 | ZKSCAN8 | ZKSCAN8P1 | ZMAT1 | ZMAT2 | ZMAT3 | ZMAT4 | ZMAT5 | ZMIZ1 | ZMIZ1-AS1 | ZMIZ2 | ZMPSTE24 | ZMYM1 | ZMYM2 | ZMYM3 | ZMYM4 | ZMYM4-AS1 | ZMYM5 | ZMYM6 | ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207